(19)
(11) EP 4 069 841 A1

(12)

(43) Date of publication:
12.10.2022 Bulletin 2022/41

(21) Application number: 20829427.2

(22) Date of filing: 01.12.2020
(51) International Patent Classification (IPC): 
C12N 15/11(2006.01)
A61K 31/7088(2006.01)
 A61K 48/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 2320/51; C12N 2310/51; C12N 15/11; C12N 2750/14143; C12N 15/85; C12N 15/86; A61K 31/7088; A61K 31/712
(86) International application number:
PCT/US2020/062671
(87) International publication number:
WO 2021/113218 (10.06.2021 Gazette 2021/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 02.12.2019 US 201962942690 P
02.12.2019 US 201962942667 P
16.04.2020 US 202063010856 P
10.11.2020 US 202063111856 P

(71) Applicant: Shape Therapeutics Inc.
Seattle, WA 98109 (US)

(72) Inventors:
  • HUSS, David
    Seattle, Washington 98109 (US)
  • STEIN, Liana
    Kenmore, Washington 98028 (US)
  • SULLIVAN, Richard
    Seattle, Washington 98103 (US)
  • LAKSHMANAN, Anupama
    Sammamish, Washington 98029 (US)
  • BURLEIGH, Stephen
    Seattle, Washington 98133 (US)

(74) Representative: Fish & Richardson P.C. 
Highlight Business Towers Mies-van-der-Rohe-Straße 8
80807 München
80807 München (DE)

   


(54) TARGETED TRANSFER RNAS FOR TREATMENT OF DISEASES